IL176500A - Use of respiratory syncytial virus with a gene encoded for protein g attachment to prevent or treat pneumoviral infection - Google Patents

Use of respiratory syncytial virus with a gene encoded for protein g attachment to prevent or treat pneumoviral infection

Info

Publication number
IL176500A
IL176500A IL176500A IL17650006A IL176500A IL 176500 A IL176500 A IL 176500A IL 176500 A IL176500 A IL 176500A IL 17650006 A IL17650006 A IL 17650006A IL 176500 A IL176500 A IL 176500A
Authority
IL
Israel
Prior art keywords
virion
mutation
prevention
treatment
gene encoding
Prior art date
Application number
IL176500A
Other languages
English (en)
Hebrew (he)
Other versions
IL176500A0 (en
Inventor
Willem Luytjes
Myra Noorely Widjojoatmodjo
Original Assignee
Nederlanden Staat
Willem Luytjes
Myra Noorely Widjojoatmodjo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat, Willem Luytjes, Myra Noorely Widjojoatmodjo filed Critical Nederlanden Staat
Publication of IL176500A0 publication Critical patent/IL176500A0/en
Publication of IL176500A publication Critical patent/IL176500A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/115Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135Respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18532Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551Methods of production or purification of viral material
    • C12N2760/18552Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • C12N2760/18562Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL176500A 2003-12-24 2006-06-22 Use of respiratory syncytial virus with a gene encoded for protein g attachment to prevent or treat pneumoviral infection IL176500A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0300930 2003-12-24
PCT/NL2004/000911 WO2005061698A1 (en) 2003-12-24 2004-12-24 A respiratory syncytial virus with a genomic deficiency complemented in trans

Publications (2)

Publication Number Publication Date
IL176500A0 IL176500A0 (en) 2006-10-05
IL176500A true IL176500A (en) 2015-02-26

Family

ID=34709376

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176500A IL176500A (en) 2003-12-24 2006-06-22 Use of respiratory syncytial virus with a gene encoded for protein g attachment to prevent or treat pneumoviral infection

Country Status (23)

Country Link
US (3) US9107939B2 (https=)
EP (2) EP2500419B1 (https=)
JP (1) JP4814799B2 (https=)
KR (1) KR101266715B1 (https=)
CN (1) CN1922309B (https=)
AU (1) AU2004303719B2 (https=)
BR (1) BRPI0418093A (https=)
CA (1) CA2551009C (https=)
CY (1) CY1118741T1 (https=)
DK (1) DK1699919T3 (https=)
EA (1) EA011878B1 (https=)
ES (2) ES2618523T3 (https=)
HU (1) HUE032898T2 (https=)
IL (1) IL176500A (https=)
LT (1) LT1699919T (https=)
NO (1) NO334756B1 (https=)
NZ (1) NZ548107A (https=)
PL (1) PL1699919T3 (https=)
PT (1) PT1699919T (https=)
SI (1) SI1699919T1 (https=)
TR (1) TR201808496T4 (https=)
WO (1) WO2005061698A1 (https=)
ZA (1) ZA200605218B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121210D0 (en) * 2011-12-09 2012-01-18 Health Prot Agency Respiratory infection assay
WO2013133702A1 (en) 2012-03-05 2013-09-12 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Methods and compositions for stabilizing dried biological materials
CN113322264B (zh) 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
BR112015031541A2 (pt) 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
CN106659777A (zh) 2014-06-13 2017-05-10 葛兰素史密丝克莱恩生物有限公司 免疫原性组合产品
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
US10626126B2 (en) * 2016-04-08 2020-04-21 Pulmocide Limited Compounds
CN112746059A (zh) * 2020-09-15 2021-05-04 清华大学 基于病毒结构蛋白遗传互补的冠状病毒细胞模型
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN114990079B (zh) * 2022-04-29 2023-07-04 广州医科大学附属第一医院(广州呼吸中心) 治疗性缺陷干扰颗粒及其在制备用于防治rsv病毒感染的产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT702085E (pt) 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
EP1035205A1 (en) 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
AU2001263896A1 (en) 2000-06-23 2002-01-14 Akzo Nobel N.V. Attenuated bovine respiratory syncytial virus
WO2003029416A2 (en) * 2001-10-01 2003-04-10 Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof

Also Published As

Publication number Publication date
CA2551009C (en) 2017-01-17
CY1118741T1 (el) 2017-07-12
JP4814799B2 (ja) 2011-11-16
US20100291035A1 (en) 2010-11-18
IL176500A0 (en) 2006-10-05
CA2551009A1 (en) 2005-07-07
ES2670713T3 (es) 2018-05-31
AU2004303719B2 (en) 2010-11-11
JP2007516721A (ja) 2007-06-28
PL1699919T3 (pl) 2017-08-31
KR101266715B1 (ko) 2013-05-28
EP2500419A1 (en) 2012-09-19
EA011878B1 (ru) 2009-06-30
US9889168B2 (en) 2018-02-13
CN1922309A (zh) 2007-02-28
NO334756B1 (no) 2014-05-19
PT1699919T (pt) 2017-04-03
WO2005061698A1 (en) 2005-07-07
US9107939B2 (en) 2015-08-18
BRPI0418093A (pt) 2007-04-17
ZA200605218B (en) 2007-05-30
US20150329833A1 (en) 2015-11-19
CN1922309B (zh) 2011-07-13
US20180207211A1 (en) 2018-07-26
SI1699919T1 (sl) 2017-07-31
EA200601218A1 (ru) 2006-12-29
DK1699919T3 (en) 2017-03-20
LT1699919T (lt) 2017-04-25
HK1100494A1 (en) 2007-09-21
HUE032898T2 (hu) 2017-11-28
NZ548107A (en) 2009-09-25
KR20070022210A (ko) 2007-02-26
AU2004303719A1 (en) 2005-07-07
EP1699919B1 (en) 2017-01-11
ES2618523T3 (es) 2017-06-21
TR201808496T4 (tr) 2018-07-23
EP2500419B1 (en) 2018-03-21
US10967014B2 (en) 2021-04-06
NO20062967L (no) 2006-09-22
EP1699919A1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
EP1594512A4 (en) COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
EP1633853A4 (en) DNA VACCINE COMPOSITIONS AGAINST SEVERE ACUTE RESPIRATORY SYNDROME AND METHODS OF USE
EP1492563A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIONS WITH THE HERPES SIMPLEX VIRUS
SG149075A1 (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
HUP0400882A3 (en) Oncolytic virus therapy
IL173909A0 (en) Use of modified cyclosporins for the treatment of hcv disorders
IL182785A0 (en) Particles for treatment of pulmonary infection
PL376409A1 (en) Composition for the treatment of infection by flaviviridae viruses
AU2003225281A8 (en) Materials and methods for prevention and treatment of rna viral diseases
PT1530466E (pt) Utilização de nintedanib para o tratamento de fibrose pulmonar
IL176500A (en) Use of respiratory syncytial virus with a gene encoded for protein g attachment to prevent or treat pneumoviral infection
GB0410399D0 (en) The treatment of respiratory disease
GB0329254D0 (en) Treatment of viral infections
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
GB0410398D0 (en) The treatment of respiratory disease
PL1670482T3 (pl) Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
GB0004531D0 (en) The treatment of respiratory diseases
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
EP1638625A4 (en) ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM
AU2003292045A8 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases
GB0329958D0 (en) Treatment of viral infections
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
EP1572108A4 (en) FUNCTIONAL MUTATIONS OF RSV (RESPIRATORY SYNCYTIAL VIRUS)
IL179046A0 (en) Treatment or prevention of respiratory viral infections with immunomodulator compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed